

Amphastar Pharmaceuticals, Inc.  
 Form 4  
 June 12, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Zhang Jack Y.

2. Issuer Name and Ticker or Trading Symbol  
 Amphastar Pharmaceuticals, Inc.  
 [AMPH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 06/05/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 CEO & Chief Science Officer

C/O AMPHASTAR  
 PHARMACEUTICALS,  
 INC., 11570 6TH STREET  
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RANCHO  
 CUCAMONGA, CA 91730  
 (City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	06/05/2015		F	4,831 (1) D \$ 16.4642	917,306	D	
Common Stock	06/08/2015		F	3,046 (1) D \$ 16.614	914,260	D	
Common Stock	06/09/2015		F	2,624 (1) D \$ 16.2356	911,636	D	
Common Stock	06/10/2015		M	12,975 A \$ 12.97	924,611	D	

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Common Stock	06/10/2015	<u>S</u> (2)	11,731	D	\$ <u>(3)</u> 16.3792	912,880	D	
Common Stock	06/10/2015	F	<u>(4)</u> 1,244	D	\$ 16.3792	911,636	D	
Common Stock	06/11/2015	M	12,860	A	\$ 12.97	924,496	D	
Common Stock	06/11/2015	<u>S</u> (2)	11,600	D	\$ <u>(5)</u> 16.4694	912,896	D	
Common Stock	06/11/2015	F	<u>(4)</u> 1,260	D	\$ 16.4694	911,636	D	
Common Stock	06/12/2015	M	83,253	A	\$ 12.97	994,889	D	
Common Stock	06/12/2015	<u>S</u> (2)	75,618	D	\$ <u>(6)</u> 16.1487	919,271	D	
Common Stock	06/12/2015	F	<u>(4)</u> 7,635	D	\$ 16.1487	911,636	D	
Common Stock	06/05/2015	F	<u>(1)</u> 6,173	D	\$ 16.4657	667,351	I	See footnote <u>(7)</u>
Common Stock	06/08/2015	F	<u>(1)</u> 3,052	D	\$ 16.6087	664,299	I	See footnote <u>(7)</u>
Common Stock	06/09/2015	F	<u>(1)</u> 2,633	D	\$ 16.2339	661,666	I	See footnote <u>(7)</u>
Common Stock	06/10/2015	M	12,619	A	\$ 12.97	674,285	I	See footnote <u>(7)</u>
Common Stock	06/10/2015	<u>S</u> (2)	11,411	D	\$ <u>(8)</u> 16.3719	662,874	I	See footnote <u>(7)</u>
Common Stock	06/10/2015	F	<u>(4)</u> 1,208	D	\$ 16.3719	661,666	I	See footnote <u>(7)</u>
Common Stock	06/11/2015	M	12,930	A	\$ 12.97	674,596	I	See footnote <u>(7)</u>
Common Stock	06/11/2015	<u>S</u> (2)	11,664	D	\$ <u>(9)</u> 16.4689	662,932	I	See footnote <u>(7)</u>

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Common Stock	06/11/2015	F	<u>1,266</u> (4)	D	\$ 16.4689	661,666	I	See footnote (7)
Common Stock	06/12/2015	M	42,223	A	\$ 12.97	703,889	I	See footnote (7)
Common Stock	06/12/2015	<u>S(2)</u>	38,471	D	\$ 16.1673 (10)	665,418	I	See footnote (7)
Common Stock	06/12/2015	F	<u>3,752</u> (4)	D	\$ 16.1673	661,666	I	See footnote (7)
Common Stock						7,631,594	I	See footnote (11)
Common Stock						5,000	I	See footnote (12)
Common Stock						200,000	I	See footnote (13)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 12.97	06/10/2015		M	12,975	<u>(14)</u>	09/28/2015	Common Stock	12,975



\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with a previously reported option exercise.
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the each of the reporting persons on December 16, 2014.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.25 to \$16.61, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5), (6), (8), (9) and (10) to this Form 4.
- (4) The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with the reported option exercise.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.38 to \$16.62, inclusive.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.02 to \$16.49, inclusive.
- (7) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- (8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.24 to \$16.55, inclusive.
- (9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.37 to \$16.61, inclusive.
- (10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.03 to \$16.39, inclusive.
- (11) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons are the sole owners.
- (12) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- (13) The shares are held of record by a trust for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- (14) Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.